Genmab — April 2026
-
this is a nice new trial! : Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers (RAINFOL-09) https://clinicaltrials.gov/study/NCT07539311
-
Der er i hvert fald ikke meget om 06 og 07 - Slet ikke om 08: RAINFOL-06 & 07: Disse forventes at dække yderligere kombinationsbehandlinger eller nye sygdomsområder (indikationer), hvor Folat Receptor alfa (FRα) er udtrykt.
Genmab har indikeret, at de vil udforske Rina-S i kombination med andre terapier (som f.eks. immunterapi eller andre målrettede midler) for at flytte behandlingen tidligere ind i sygdomsforløbet. -
-
Det er AI: Genmab's strategic investor materials and recent pipeline updates indicate plans to expand Rina-S (Rinatabart Sesutecan) studies, including anticipated developments in late-stage portfolios that likely cover combinations such as RAINFOL-06 and 07. These materials indicate a focus on assessing Rina-S in combination with bevacizumab or immunotherapy, building on data from the RAINFOL-01 trial
-
Information om RAINFOL-06 og -07 studiernes fokus på yderligere kombinationsbehandlinger og nye indikationer for Folat Receptor alfa (FRα) findes i Genmabs investorpræsentationer og opdaterede pipelinedokumenter. Disse strategiske udvidelser og den generelle Rina-S programacceleration beskrives i selskabets finansielle rapporter, herunder materialer relateret til deres Q3 2025 Interim Report og 2025 Annual Report
-
Genmab i kridthuset hos Goldman: Ser potentiale på 27 pct. https://proinvestor.com/investornyt/1434655/genmab-i-kridthuset-hos-goldman-ser-potentiale-pa-27-pct
-
ok, so AI does not know more than we do. RAINFOL-06 to 08 was not mentioned anywhere before. It is logical to assume these names are in use for other indications so we'll have to wait to see which indications they are and if initial data is sufficiently strong to bring them into trial. Breast cancer maybe?
-
-
"The winner takes it all" . Det globale aktiemarked er presset for tiden - men for NASDAQ-indekset i USA kører det forrygende. Der sættes hele tiden nye kursrekorder trods krig, stigende oliepriser osv. Helge Larsen ser på årsagerne og kommer sidst i ugekommentaren også ind på, hvorfor pharma ikke er en sikker havn i disse urolige tider. Kort video: https://proinvestor.com/boards/132062
-
Petosemtamab Ph3 goes from 500 to 700 patients , same completion dates
https://clinicaltrials.gov/study/NCT06525220
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind